Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
暂无分享,去创建一个
S. Nahas | J. Lancet | T. Cluzeau | E. Padron | M. Mcginniss | D. Sallman | R. Komrokji | G Mufti | DA Sallman | R Komrokji | C Vaupel | T Cluzeau | SM Geyer | KL McGraw | NH Al Ali | J Lancet | MJ McGinniss | S Nahas | AE Smith | A Kulasekararaj | A List | J Hall | E Padron | A. Kulasekararaj | K. McGraw | A. List | S. Geyer | N. A. Ali | J. Hall | C. Vaupel | S. Geyer | G. Mufti | M. McGinniss | Ae Smith | N. Ali | A. Smith | M J McGinniss
[1] M. Calasanz,et al. Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression , 2015, Leukemia.
[2] G. Mufti,et al. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS) , 2015, Leukemia.
[3] H. Rehm,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[4] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[5] P. Campbell,et al. TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee , 2014 .
[6] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[7] D. Neuberg,et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.
[8] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Campbell,et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. , 2014, Blood.
[10] C. Preudhomme,et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.
[11] Christopher A. Miller,et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.
[12] M. Cazzola,et al. The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.
[13] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[14] D. Birnbaum,et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Mufti,et al. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome , 2013, Haematologica.
[16] G. Mufti,et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis , 2013, British journal of haematology.
[17] Ken Chen,et al. Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.
[18] Peter J Campbell,et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.
[19] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[20] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[21] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[22] Eva Hellström-Lindberg,et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[24] F. Passamonti,et al. Clinical relevance of JAK2 (V617F) mutant allele burden , 2009, Haematologica.
[25] B. Ko,et al. RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome , 2007, British journal of haematology.
[26] M. Taniwaki,et al. Configuration of the TP53 Gene as an Independent Prognostic Parameter of Myelodysplastic Syndrome , 2003, Leukemia & lymphoma.
[27] M. Taniwaki,et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome , 2001, British journal of haematology.
[28] H. Kaneko,et al. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. , 1995, Blood.
[29] R. Berger,et al. Mutations in the p53 gene in myelodysplastic syndromes. , 1991, Oncogene.